Program
aflibercept
Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.
Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 251 open or running | phase 4since Nov 2, 2012 | May 13, 2002 | none ahead |
| Bayerits history only | 230 open or running | phase 4since Apr 10, 2014 | Mar 12, 2008 | none ahead |
| Sanofiits history only | 200 open or running | phase 3since May 16, 2006 | Jan 30, 2006 | none ahead |
| Novartisits history only | 40 open or running | phase 4since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Amgenits history only | 31 open or running | phase 3since Feb 13, 2020 | Feb 13, 2020 | Jul 31, 2027phase 3 · NCT07614776 |
| Sam Chun Dang Pharm.its history only | 20 open or running | phase 3since Jul 17, 2020 | Jul 17, 2020 | none ahead |
| AbbVieits history only | 11 open or running | phase 2since Mar 16, 2022 | Mar 16, 2022 | Jun 2031phase 2 · NCT05296447 |
| AO GENERIUMits history only | 11 open or running | phase 3since Sep 18, 2026 | Sep 18, 2026 | May 2028phase 3 · NCT07844148 |
| Bioeqits history only | 10 open or running | phase 3since Aug 11, 2020 | Aug 11, 2020 | none ahead |
| Cinnagenits history only | 10 open or running | phase 3since Sep 18, 2022 | Sep 18, 2022 | none ahead |
| Exegenesis Bioits history only | 11 open or running | phase 1since Jan 30, 2025 | Jan 30, 2025 | Feb 2029phase 1 · NCT06817343 |
| Formyconits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 19, 2022 | Apr 19, 2022 | none ahead |
| Samsung Bioepisits history only | 10 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | none ahead |
| The Emmesits history only | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
Also a collaborator on its studies: REGENXBIO and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 11 studies since May 13, 2002.
- Jul 10, 2009Phase 3 study in Macular EdemaNCT00943072 · 189 enrolled · United States, Canada, Colombia and more
- Aug 20, 2009Phase 3 study in Macular DegenerationNCT00964795 · 323 enrolled · United States, Canada
- May 27, 2011Phase 3 study in Diabetic RetinopathyNCT01363440 · 466 enrolled · United States
- Jan 26, 2012Phase 3 study in Retinal Vein OcclusionNCT01521559 · 183 enrolled · United States, Canada, Japan
- Nov 2, 2012Phase 4 study in Macular DegenerationNCT01722045 · 154 enrolled · United States
- Apr 13, 2015Phase 2 study in Neovascular Age-Related Macular DegenerationNCT02418754 · 505 enrolled · United States, Japan
- Mar 14, 2016Phase 2 study in Diabetic Macular EdemaNCT02712008 · 302 enrolled · United States
- Mar 20, 2016Phase 3 study in Nonproliferative Diabetic RetinopathyNCT02718326 · 402 enrolled · United States, Germany, Hungary and more
- Dec 5, 2018Phase 4 study in Chorioretinal Vascular DiseaseNCT03767738 · 65 enrolled · United States
- Sep 23, 2019Phase 3 study in Retinopathy of PrematurityNCT04101721 · 127 enrolled · United States, Bulgaria, Colombia and more
- Oct 11, 2019Phase 2 study in Macular DegenerationNCT04126317 · 106 enrolled · United States, Puerto Rico
- May 26, 2020Phase 3 study in Diabetes Mellitus, Type 1NCT04429503 · 660 enrolled · United States, Canada, Czechia and more
- Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127
- Aug 3, 2023Phase 3 study in Diabetic Macular Edema (DME)NCT05989126 · 35 enrolled · United States
- Jul 1, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationNCT06491914 · 1,126 enrolled · United States, Puerto Rico
TargetBeta
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule
Studies
All 25 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06491914Neovascular Age-Related Macular Degeneration · United States, Puerto Rico | 3 | Active, not recruiting | Aug 26, 2025 | 1,126 |
| NCT05989126Diabetic Macular Edema (DME) · United States | 3 | Completed | May 31, 2024 | 35 |
| NCT04429503Diabetes Mellitus, Type 1 · United States, Canada, Czechia and more | 3 | Completed | May 30, 2022 | 660 |
| NCT04126317Macular Degeneration · United States, Puerto Rico | 2 | Completed | May 14, 2021 | 106 |
| NCT04101721Retinopathy of Prematurity · United States, Bulgaria, Colombia and more | 3 | Completed | Aug 18, 2022 | 127 |
| NCT03767738Chorioretinal Vascular Disease · United States | 4 | Completed | Aug 19, 2020 | 65 |
| NCT02718326Nonproliferative Diabetic Retinopathy · United States, Germany, Hungary and more | 3 | Completed | Aug 6, 2018 | 402 |
| NCT02712008Diabetic Macular Edema · United States | 2 | Completed | Jul 10, 2017 | 302 |
| NCT02418754Neovascular Age-Related Macular Degeneration · United States, Japan | 2 | Terminated | Aug 17, 2016 | 505 |
| NCT01722045Macular Degeneration · United States | 4 | Completed | Sep 2015 | 154 |
| NCT01521559Retinal Vein Occlusion · United States, Canada, Japan | 3 | Completed | Aug 2013 | 183 |
| NCT01363440Diabetic Retinopathy · United States | 3 | Completed | Jan 2013 | 466 |
| NCT00964795Macular Degeneration · United States, Canada | 3 | Completed | Aug 2013 | 323 |
| NCT00943072Macular Edema · United States, Canada, Colombia and more | 3 | Completed | Oct 2010 | 189 |
| NCT00794417Carcinoma, Non-Small-Cell Lung · United States, Canada | 2 | Terminated | Jun 30, 2011 | 60 |
| NCT00789477Diabetic Macular Edema · United States, Austria, Canada | 2 | Completed | Dec 2009 | 221 |
| NCT00509795Macular Degeneration · United States, Canada | 3 | Completed | Sep 2010 | 1,217 |
| NCT00383370Neovascular Age Related Macular Degeneration · United States | 1 | Completed | Sep 2007 | 20 |
| NCT00320814Diabetic Macular Edema · United States | 1 | Completed | Aug 2006 | 5 |
| NCT00320788Macular Degeneration · United States | 2 | Completed | Jun 2008 | 159 |
| NCT00320775Macular Degeneration · United States | 1 | Completed | Jun 2008 | 51 |
| NCT00083213Neoplasms · United States | 1 | Completed | May 2008 | 25 |
| NCT00082823Neoplasms · United States | 1 | Completed | May 2008 | 25 |
| NCT00045266Lymphoma · United States | 1 | Completed | Feb 2007 | |
| NCT00036946Lymphoma · United States | 1 | Completed | Mar 2002 |
How it is read
Names in the registry
- “Aflibercept”, 9 entries
- “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept”, 7 entries
- “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries
Codes read as this program: BAY865321, SCD411.
Conditions, from the studies’ own filings
- Macular Degeneration, 28 studies
- Macular Edema, 15 studies
- Colorectal Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Retinal Vein Occlusion, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.